IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...
Autors principals: | , , , , , , , |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
MDPI AG
2024-06-01
|
Col·lecció: | Pharmaceutics |
Matèries: | |
Accés en línia: | https://www.mdpi.com/1999-4923/16/7/870 |